ONVO has performed its first 3D Liver tissue delivery and also introduced updated guidance on the timing of its product launch. Organovo had planned to launch its 3D Liver tissue product by the end of December, but now expects to commence the commercial launch and start generating revenue through a services model prior to 12/14. ONVO anticipates that preclinical toxicology testing services can command prices in the high tens of thousands of dollars per compound for standard screening for liver alone. ONVO is UP as usual on large volume whether it is positive and negative but, it is still under 1/2/14’s $11.29. Great trading platform as traders “inhale and exhale once the high kicks-in”. Let ONVO run for a few days and then SELL on this news!
ASTM didn’t and probably … couldn’t raise money during its last run-up but it still pilfers its long standing retail investors … even more. SELL if you still have a stomach lining left! I noticed ASTM did NOT note the remuneration of the ATM in the release; selective disclosure? "As consideration for its commitment to purchase shares of Common Stock pursuant to the Purchase Agreement ... ASTM ... agreed to issue to Lincoln Park up to 96,126 shares of Common Stock (48,063 shares issued to Lincoln Park upon execution of the Purchase Agreement and 48,063 shares to be issued, if at all, immediately upon the filing of an additional registration statement to cover any remaining shares not covered by the Initial Registration)".
ASTM closed at $3.42 DOWN -$0.29 or -7.82% and is further DOWN -$0.07 or -2.05% to $3.35.
When is enough … for this charade? Interesting notice it has … “no limitations on use of proceeds, financial covenants, restrictions on future financings, rights of first refusal, participation rights, penalties or liquidated damages”. We all have our opinions!!